<DOC>
	<DOCNO>NCT01235910</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy blood pressure medication , aliskiren , heart transplant patient . In term safety , investigator evaluate blood level aliskiren determine aliskiren alters blood level anti-rejection medication , cyclosporine , patient . In term efficacy , investigator determine well aliskiren lower blood pressure heart transplant patient .</brief_summary>
	<brief_title>Clinical Pharmacology Aliskiren Combination With Cyclosporine Cardiac Transplantation</brief_title>
	<detailed_description>Hypertension major complication follow cardiac transplantation , prevalence 93 % 5 year post-transplant . Post-cardiac transplant hypertension due multiple factor use cyclosporine , chronic kidney disease , denervation . Hypertension population difficult treat , patient require therapy multiple antihypertensive agent order achieve adequate blood pressure control . Aliskiren , direct renin inhibitor , novel antihypertensive agent unique mechanism action potent blood pressure-lowering effect . As , aliskiren attractive treatment option post-cardiac transplant hypertension . Our study characterize pharmacokinetic drug-drug interaction profile , pharmacodynamics , safety aliskiren 75 mg daily ( low-dose ) 150 mg daily , give combination cyclosporine , cardiac transplant patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>6 month since cardiac transplant Clinically stable transplant perspective Maintained stable immunosuppressant regimen contain cyclosporine + antiproliferative agent ( e.g. , azathioprine , mycophenolate ) , +/ oral steroid Hypertension , define seat average systolic blood pressure ≥ 140 mm Hg seat average diastolic blood pressure ≥ 90 mm Hg , base 3 separate measurement , space 2 minute apart . Clinical instability cardiac transplant perspective Contraindications aliskiren therapy Conditions may increase risk aliskiren adverse effect Severe hypertension Concomitant medication know increase decrease aliskiren plasma exposure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Cardiac transplantation</keyword>
	<keyword>Aliskiren</keyword>
	<keyword>Cyclosporine</keyword>
</DOC>